
Prognosia Breast, an AI-driven mammography tool, receives FDA Breakthrough Device status for improved five-year breast cancer risk prediction.
Key Details
- 1FDA granted Breakthrough Device designation to Prognosia Breast, an AI mammography analysis tool.
- 2Developed by Washington University School of Medicine experts.
- 3Tool predicts five-year breast cancer risk from mammogram findings.
- 4Claims to be twice as accurate as current risk assessment methods.
- 5Aims to inform decisions on supplemental imaging and genetic testing.
Why It Matters

Source
Health Imaging
Related News

AI-Powered Quantitative MRI Aids Diffuse Glioma Management
Deep learning with quantitative MRI enables noninvasive treatment planning and molecular profiling of adult diffuse gliomas.

DeepHealth AI Suite Expands Radiology Insights Across Modalities
DeepHealth's Radiology AI Suite enables radiologists to detect more findings and extract additional risk and disease progression information from a wide range of imaging exams.

Deep Learning on PSMA-PET Outperforms Tools in Prostate Cancer Survival Prediction
Deep learning models using PSMA-PET scans predict survival in metastatic prostate cancer more accurately than established clinical tools.